In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively.This episode is presented in partnership with <a rel="noopener noreferrer nofollow" href="https://www.arvinas.com/" target="_blank">Arvinas</a>. Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">Jennifer Smith-Parker</a>, Director of Insights, BioSpaceGuest<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/randyteel/" target="_blank">Randy Teel</a>, President and CEO, Arvinas

The next treatment-resistant depression paradigm

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.